Redefining multiple sclerosis therapy through microbial immunomodulation and epigenetic control.

Area of Science:

• Neuroimmunology
• Molecular Biology
• Epigenetics

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease causing central nervous system demyelination and neurodegeneration.
• Immune cells, particularly T and B cells, play a critical role in MS pathogenesis.
• Dysregulated molecular signaling pathways and cell death contribute significantly to disease progression.

Purpose of the Study:

• To review the immunological, molecular, and epigenetic factors contributing to MS.
• To highlight the involvement of specific signaling pathways and cell death mechanisms.
• To explore novel therapeutic strategies for MS.

Main Methods:

• Literature review of immunological, molecular, and epigenetic mechanisms in MS.
• Analysis of current and emerging therapeutic approaches for MS treatment.
• Emphasis on T and B cell roles and signaling pathway dysregulation.

Main Results:

• Identified key roles for T and B cells, dysregulated TGF-β, Akt, and Wnt signaling pathways.
• Highlighted the impact of epigenetic modifications like DNA methylation and histone modifications on immune responses in MS.
• Noted that current MS therapies broadly suppress immunity.

Conclusions:

• Emerging therapies like engineered bacteria, microbiome interventions, and cell therapies offer targeted immune modulation and neuroprotection.
• These novel strategies represent a path toward more precise and effective next-generation MS treatments.
• Understanding the complex interplay of immunology, molecular biology, and epigenetics is crucial for advancing MS therapy.